Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer

被引：0
|
作者：
Novello, Silvia [1 ]
Rudell, Katja [2 ]
Bodnar, Carolyn [2 ]
Vowler, Sarah [2 ]
Rupnik, Tina [3 ]
Ghiorghiu, Serban [2 ]
机构：
[1] Univ Turin, Dept Oncol, Turin, Italy
[2] Astrazeneca, Cambridge, England
[3] Phastar, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
osimertinib; symptoms; Non-small-cell lung cancer; Patient-reported outcomes;
D O I：
10.1016/j.jtho.2016.11.1747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-080
引用
收藏
页码：S1238 / S1239
页数：2
相关论文
共 50 条
  • [41] Treatment of advanced non-small-cell lung cancer in the elderly
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Marianna Luciana
    Castaldo, Vincenzo
    Palazzolo, Giovanni
    Mazzeo, Nicole
    LUNG CANCER, 2009, 66 (03) : 282 - 286
  • [42] Docetaxel in the treatment of advanced non-small-cell lung cancer
    Saloustros, Emmanouel
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1207 - 1222
  • [43] Necitumumab for the treatment of advanced non-small-cell lung cancer
    Diaz-Serrano, Asuncion
    Sanchez-Torre, Ana
    Paz-Ares, Luis
    FUTURE ONCOLOGY, 2019, 15 (07) : 705 - 716
  • [44] Patient-Reported Outcomes as Interradiographic Predictors of Response in Non-Small Cell Lung Cancer
    Bhatt, Ambika S.
    Schabath, Matthew B.
    Hoogland, Aasha I.
    Jim, Heather S. L.
    Brady-Nicholls, Renee
    CLINICAL CANCER RESEARCH, 2023, 29 (16) : 3142 - 3150
  • [45] Molecular Dynamics Simulation of EFGR L844V Mutant Sensitive to AZD9291 in Non-Small Cell Lung Cancer
    Assadollahi, Vahideh
    Rashidieh, Behnam
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1210 - S1210
  • [46] SYSTEMATIC REVIEW OF THE IMPACT OF CHEMOTHERAPY ON PATIENT REPORTED OUTCOMES IN ADVANCED NON-SMALL-CELL LUNG CANCER
    Goulart, B. H. L.
    Sullivan, S. D.
    Garrison, L. P.
    Ramsey, S.
    Martins, R.
    Patrick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A499 - A499
  • [47] CLINICALLY MEANINGFUL DIFFERENCES IN PATIENT-REPORTED OUTCOMES WITH AMIFOSTINE IN COMBINATION WITH CHEMORADIATION FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: AN ANALYSIS OF RTOG 9801
    Sarna, Linda
    Swann, Suzanne
    Langer, Corey
    Werner-Wasik, Maria
    Nicolaou, Nicos
    Komaki, Ritsuko
    Machtay, Mitchell
    Byhardt, Roger
    Wasserman, Todd
    Movsas, Benjamin
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (05): : 1378 - 1384
  • [48] Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
    Huang, Jing
    Wang, Yiyin
    Zhai, Yachao
    Wang, Jin
    THORACIC CANCER, 2018, 9 (06) : 745 - 749
  • [49] TIME ELAPSED BETWEEN SYMPTOM ONSET, MEDICAL CONSULTATION, DIAGNOSIS AND TREATMENT IN PATIENT WITH ADVANCED NON-SMALL-CELL LUNG CANCER
    Richardet, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 346 - 346
  • [50] Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
    Chen, Jingyu
    Zhao, Xueqi
    Wang, Jinlin
    Liu, Fangfang
    Zhang, Linli
    Chen, Yuan
    Chu, Qian
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (09) : 3343 - 3348
12345